• 1
    Franceschini N, Napravnik S, Eron JJ, Szczech LA, Finn WF. Incidence and etiology of acute renal failure among ambulatory HIV-infected patients. Kidney Int 2005; 67: 15261531.
  • 2
    Ibrahim F, Naftalin C, Cheserem E et al. Immunodeficiency and renal impairment are risk factors for HIV-associated acute renal failure. AIDS 2010; 24: 22392244.
  • 3
    Roe J, Campbell LJ, Ibrahim F, Hendry BM, Post FA. HIV care and the incidence of acute renal failure. Clin Infect Dis 2008; 47: 242249.
  • 4
    Kalim S, Szczech LA, Wyatt CM. Acute kidney injury in HIV-infected patients. Semin Nephrol 2008; 28: 556562.
  • 5
    Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El-Sadr WM, Lundgren J, Neaton JD et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355: 22832296.
  • 6
    Lucas GM, Eustace JA, Sozio S, Mentari EK, Appiah KA, Moore RD. Highly active antiretroviral therapy and the incidence of HIV-1-associated nephropathy: a 12-year cohort study. AIDS 2004; 18: 541546.
  • 7
    Mocroft A, Kirk O, Gatell J et al. Chronic renal failure among HIV-1-infected patients. AIDS 2007; 21: 11191127.
  • 8
    Mocroft A, Kirk O, Reiss P et al.; EuroSIDA Study Group. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS 2010; 24: 16671678.
  • 9
    Zimmermann AE, Pizzoferrato T, Bedford J, Morris A, Hoffman R, Braden G. Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clin Infect Dis 2006; 42: 283290.
  • 10
    Lepist EI, Ray AS. Renal drug-drug interactions: what we have learned and where we are going. Expert Opin Drug Metab Toxicol 2012; 8: 433448.
  • 11
    Thompson MA, Aberg JA, Cahn P et al.; International AIDS Society-USA. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010; 304: 321333.
  • 12
    Gallant JE, Parish MA, Keruly JC, Moore RD. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis 2005; 40: 11941198.
  • 13
    Parsonage MJ, Wilkins EG, Snowden N, Issa BG, Savage MW. The development of hypophosphataemic osteomalacia with myopathy in two patients with HIV infection receiving tenofovir therapy. HIV Med 2005; 6: 341346.
  • 14
    McMorran M. Tenofovir (viread) and NSAIDs: acute renal failure. Can Adver React Newslett 2006; 16: 12.
  • 15
    Bpharm SM, Talbot A, Trottier B. Acute renal failure in four HIV-infected patients: potential association with tenofovir and nonsteroidal anti-inflammatory drugs. Can J Infect Dis Med Microbiol 2008; 19: 7576.
  • 16
    Madeddu G, Bonfanti P, De Socio GV et al.; CISAI Group. Tenofovir renal safety in HIV-infected patients: results from the SCOLTA Project. Biomed Pharmacother 2008; 62: 611.
  • 17
    Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461470.
  • 18
    National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39 (2 Suppl 1): S1266.
  • 19
    Mehta RL, Kellum JA, Shah SV et al.; Acute Kidney Injury Network. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007; 11: R31.
  • 20
    Murray MD, Brater DC. Effects of NSAIDs on the kidney. Prog Drug Res 1997; 49: 155171.
  • 21
    Hasse B, Ledergerber B, Furrer H et al.; Swiss HIV Cohort Study. Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study. Clin Infect Dis 2011; 53: 11301139.
  • 22
    Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis 2010; 51: 496505.
  • 23
    Lopes JA, Melo MJ, Viegas A et al. Acute kidney injury in hospitalized HIV-infected patients: a cohort analysis. Nephrol Dial Transplant 2011; 26: 38883894.
  • 24
    Bagshaw SM, Laupland KB, Doig CJ et al. Prognosis for long-term survival and renal recovery in critically ill patients with severe acute renal failure: a population-based study. Crit Care 2005; 9: R700R709.
  • 25
    Fernandez-Fernandez B, Montoya-Ferrer A, Sanz AB et al. Tenofovir nephrotoxicity: 2011 update. AIDS Res Treat 2011; 2011: 354908.
  • 26
    Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency. Am J Kidney Dis 2002; 39: 930936.
  • 27
    Chertow GM, Burdick E, Honour M, Bonventre JV, Bates DW. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol 2005; 16: 33653370.
  • 28
    Wyatt CM, Arons RR, Klotman PE, Klotman ME. Acute renal failure in hospitalized patients with HIV: risk factors and impact on in-hospital mortality. AIDS 2006; 20: 561565.
  • 29
    Choi AI, Li Y, Parikh C, Volberding PA, Shlipak MG. Long-term clinical consequences of acute kidney injury in the HIV-infected. Kidney Int 2010; 78: 478485.
  • 30
    Nelson MR, Katlama C, Montaner JS et al. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS 2007; 21: 12731281.
  • 31
    Morelle J, Labriola L, Lambert M, Cosyns JP, Jouret F, Jadoul M. Tenofovir-related acute kidney injury and proximal tubule dysfunction precipitated by diclofenac: a case of drug-drug interaction. Clin Nephrol 2009; 71: 567570.
  • 32
    Bam R, Yant S, Cihla T. Tenofovir alafenamide (GS-7340) is not a substrate for renal organic anion transporters (OAT) and does not exhibit OAT-dependent cytotoxicity. Abstract 540; Conference on Retroviruses and Opportunistic Infections (CROI); Atlanta, Georgia, USA, 2013.